Benefit — GMLP + TPLC stance
What Snapshot-grade GMLP evidence actually saves you
The Action Plan is a direction, not a rule. But GMLP principles show up in every serious FDA conversation about AI-in-trials. Having the record on file changes the shape of that conversation.
The three moments where it matters
- Pre-IND / IND-amendment discussion. AI-in-trial mention triggers GMLP-shaped reviewer questions. Dated monitoring evidence keeps the response on merits.
- Type C meeting. "How do you monitor real-world performance of the AI you're using?" is now a standard reviewer question. Snapshot answers it directly.
- BIMO inspection. Inspectors increasingly probe AI-monitoring practices as part of trial-conduct review. Independent evidence flattens the probe.
Dollar frame
Reviewer-response cycle cost: a single round of FDA information-request follow-up on AI-monitoring gaps typically runs $250K-$1.5M in Reg Affairs + external counsel + biostats reprocessing.
Trial-hold risk: a serious GMLP finding during BIMO can trigger a partial or full clinical hold. Per-day cost of a Phase III hold typically runs $50K-$500K depending on program burn.
Preventive discipline cost: $499 Snapshot produces independent TPLC-monitoring evidence on the actual trial-AI surface.
Who at your org cares
- VP Regulatory Affairs — FDA meeting + BIMO stance
- Chief AI Officer / Data Science lead — GMLP practice documentation
- Head of Clinical Development — trial-hold risk mitigation
- Chief Quality Officer — sponsor QMS + GMLP fit
What "having it" looks like
Green: Snapshot on file. Dated drift-event log. Signed independent-verifier declaration. FDA GMLP question answered with a record.
Red: No independent monitoring on file. The clinical-AI vendor's dashboard is the response. Reviewer probes deeper. Trial-hold risk crystallizes if the probe surfaces uncaught drift.
$499. 3 business days.
The independent GMLP + TPLC monitoring evidence FDA reviewers now expect — on your actual trial-AI surface.
Buy $499